Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells 64,197 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 64,197 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the transaction, the insider now directly owns 153,544 shares in the company, valued at $379,253.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jay David Caplan also recently made the following trade(s):

• On Thursday, September 12th, Jay David Caplan sold 65,000 shares of Fractyl Health stock. The stock was sold at an average price of $2.90, for a total value of $188,500.00.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $2.37 on Thursday. Fractyl Health, Inc. has a twelve month low of $1.74 and a twelve month high of $14.50. The stock’s 50 day moving average is $2.63 and its 200-day moving average is $4.05. The company has a quick ratio of 7.46, a current ratio of 7.46 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $113.59 million and a price-to-earnings ratio of -0.19.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million for the quarter. Sell-side analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Trading of Fractyl Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its position in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after buying an additional 7,397 shares during the last quarter. Rhumbline Advisers purchased a new position in Fractyl Health during the 2nd quarter worth $32,000. SG Americas Securities LLC bought a new stake in shares of Fractyl Health in the 3rd quarter worth $33,000. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health in the second quarter valued at about $61,000. Finally, Beta Wealth Group Inc. bought a new position in shares of Fractyl Health during the third quarter valued at about $44,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.